Helen E Dinkelspiel1, Ana I Tergas2, Lilli A Zimmerman1, William M Burke3, June Y Hou3, Ling Chen1, Grace Hillyer4, Alfred I Neugut5, Dawn L Hershman5, Jason D Wright6. 1. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, USA. 2. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, USA; Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, USA; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, USA; New York Presbyterian Hospital, USA. 3. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, USA; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, USA; New York Presbyterian Hospital, USA. 4. Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, USA. 5. Department of Medicine, Columbia University College of Physicians and Surgeons, USA; Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, USA; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, USA; New York Presbyterian Hospital, USA. 6. Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, USA; Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, USA; New York Presbyterian Hospital, USA. Electronic address: jw2459@columbia.edu.
Abstract
OBJECTIVE: Although 5-year survival for early-stage ovarian cancer is favorable, prognosis at recurrence is poor, necessitating appropriate initial management. We examined the patterns of care and the impact of the duration of chemotherapy on survival for women with early-stage ovarian cancer. METHODS: We used the SEER-Medicare database to identify women ≥ 65 years of age with stage I ovarian cancer diagnosed from 1992 to 2009. Patients were categorized as low-risk (non-clear cell histology, stage IA or IB, grade 1 or 2) or high-risk (clear cell histology, grade 3, or stage IC). We used multivariable logistic regression models to determine predictors of chemotherapy use and duration and Cox proportional hazards models to evaluate the effect of chemotherapy use and duration on survival. RESULTS: We identified 1394 patients. Among low-risk patients, 32.9% received adjuvant chemotherapy and the use of chemotherapy increased with time. Among high-risk patients, 71.9% received adjuvant chemotherapy; 44.2% had ≤ 3 months of treatment, and 55.8% had > 3 months of treatment. Older patients were less likely to receive chemotherapy, while those with higher stage and grade were more likely to receive chemotherapy (P<0.05 for all). Among high-risk patients, the duration of chemotherapy did not impact overall (HR=0.93, 95% CI, 0.67-1.27) or cancer specific (HR=0.93; 95% CI, 0.61-1.42) survival. CONCLUSIONS: Among early-stage ovarian cancer patients, practice patterns are widely divergent. Extended duration chemotherapy does not appear to impact survival for women with high-risk disease.
OBJECTIVE: Although 5-year survival for early-stage ovarian cancer is favorable, prognosis at recurrence is poor, necessitating appropriate initial management. We examined the patterns of care and the impact of the duration of chemotherapy on survival for women with early-stage ovarian cancer. METHODS: We used the SEER-Medicare database to identify women ≥ 65 years of age with stage I ovarian cancer diagnosed from 1992 to 2009. Patients were categorized as low-risk (non-clear cell histology, stage IA or IB, grade 1 or 2) or high-risk (clear cell histology, grade 3, or stage IC). We used multivariable logistic regression models to determine predictors of chemotherapy use and duration and Cox proportional hazards models to evaluate the effect of chemotherapy use and duration on survival. RESULTS: We identified 1394 patients. Among low-risk patients, 32.9% received adjuvant chemotherapy and the use of chemotherapy increased with time. Among high-risk patients, 71.9% received adjuvant chemotherapy; 44.2% had ≤ 3 months of treatment, and 55.8% had > 3 months of treatment. Older patients were less likely to receive chemotherapy, while those with higher stage and grade were more likely to receive chemotherapy (P<0.05 for all). Among high-risk patients, the duration of chemotherapy did not impact overall (HR=0.93, 95% CI, 0.67-1.27) or cancer specific (HR=0.93; 95% CI, 0.61-1.42) survival. CONCLUSIONS: Among early-stage ovarian cancerpatients, practice patterns are widely divergent. Extended duration chemotherapy does not appear to impact survival for women with high-risk disease.
Authors: Jason D Wright; Thomas J Herzog; Alfred I Neugut; William M Burke; Yu-Shiang Lu; Sharyn N Lewin; Dawn L Hershman Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Deborah Schrag; Craig Earle; Feng Xu; Katherine S Panageas; K Robin Yabroff; Robert E Bristow; Edward L Trimble; Joan L Warren Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Craig C Earle; Deborah Schrag; Bridget A Neville; K Robin Yabroff; Marie Topor; Angela Fahey; Edward L Trimble; Diane C Bodurka; Robert E Bristow; Michael Carney; Joan L Warren Journal: J Natl Cancer Inst Date: 2006-02-01 Impact factor: 13.506
Authors: Desiree F Kolomainen; Roger A'Hern; Fareeda Y Coxon; Cyril Fisher; D Michael King; Peter R Blake; Desmond P J Barton; John H Shepherd; Stanley B Kaye; Martin E Gore Journal: J Clin Oncol Date: 2003-08-15 Impact factor: 44.544
Authors: Xianglin L Du; Shenying Fang; Sally W Vernon; Hashem El-Serag; Y Tina Shih; Jessica Davila; Monica L Rasmus Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: Barbara A Goff; Barbara J Matthews; Eric H Larson; C Holly A Andrilla; Michelle Wynn; Denise M Lishner; Laura-Mae Baldwin Journal: Cancer Date: 2007-05-15 Impact factor: 6.860
Authors: J Baptist Trimbos; Mahesh Parmar; Ignace Vergote; David Guthrie; Giorgio Bolis; Nicoletta Colombo; Jan B Vermorken; Valter Torri; Constantino Mangioni; Sergio Pecorelli; Andrea Lissoni; Ann Marie Swart Journal: J Natl Cancer Inst Date: 2003-01-15 Impact factor: 13.506
Authors: Miriam Champer; Yongmei Huang; June Y Hou; Ana I Tergas; William M Burke; Grace Clarke Hillyer; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2017-11-16 Impact factor: 5.482